AR026631A1 - ''3-4-dihidroquinazolinas 5,6-disustituidas'' - Google Patents
''3-4-dihidroquinazolinas 5,6-disustituidas''Info
- Publication number
- AR026631A1 AR026631A1 ARP000106257A ARP000106257A AR026631A1 AR 026631 A1 AR026631 A1 AR 026631A1 AR P000106257 A ARP000106257 A AR P000106257A AR P000106257 A ARP000106257 A AR P000106257A AR 026631 A1 AR026631 A1 AR 026631A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compound
- patient
- pharmaceutically acceptable
- platelet count
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se ha encontrado que los compuestos de formula (1) (en donde X e Y, que pueden ser iguales o diferentes, representan cada uno Cl, Br, o F) y tautomeros delos mismos, tienen mejores propiedades de reduccion del recuento de plaquetas. También se propor cionan métodos para preparar sintéticamente los compuestos deformula (1) y sales de adicion farmacéuticamente aceptables de los mismos y un método para reducir el recuento de plaquetas en un paciente mediante laadministracion al paciente de una canti dad efectiva reductora de plaquetas de un compuesto de la formula (1) preferentemente junto con un portadorfarmacéuticamente aceptable. También se proporciona una composicion farmacéutica que contiene un compuesto de formula (1) como ingrediente acti vo junto conexcipientes farmacéuticamente aceptables. Además se proporciona un compuesto de formula (1) para uso en terapia y el uso de un compuesto de formlula (1) parapreparar un medicamento para reducir el recuento de plaquetas en un paciente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/452,008 US6194420B1 (en) | 1999-11-30 | 1999-11-30 | 2-amino-5,6-dichloro-3,4-dihydroquinazoline, its method of making and using and pharmaceutical compositions thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
AR026631A1 true AR026631A1 (es) | 2003-02-19 |
Family
ID=23794633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000106257A AR026631A1 (es) | 1999-11-30 | 2000-11-28 | ''3-4-dihidroquinazolinas 5,6-disustituidas'' |
Country Status (6)
Country | Link |
---|---|
US (1) | US6194420B1 (es) |
AR (1) | AR026631A1 (es) |
AU (1) | AU1538101A (es) |
CA (1) | CA2392630C (es) |
UY (1) | UY26459A1 (es) |
WO (1) | WO2001040196A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10301105B4 (de) * | 2003-01-09 | 2005-11-24 | Chemisch-Pharmazeutisches Labor, Rolf Sachse Gmbh | Verwendung von 2-Amino-2H-chinazolin-Derivaten zur Behandlung von myeloproliferativen Erkrankungen, Bluthochdruck und Bronchodilation |
PT1589973E (pt) * | 2003-01-23 | 2010-07-09 | Shire Holdings Ag | FORMULAÃO E MéTODOS PARA O TRATAMENTO DE TROMBOCITEMIA |
US20060030574A1 (en) * | 2004-08-04 | 2006-02-09 | Shire Holdings Ag | Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors |
US7700608B2 (en) * | 2004-08-04 | 2010-04-20 | Shire Holdings Ag | Quinazoline derivatives and their use in the treatment of thrombocythemia |
CN101208309B (zh) | 2005-06-27 | 2010-12-08 | 弗·哈夫曼-拉罗切有限公司 | 氯取代的胍类化合物 |
US8304420B2 (en) * | 2006-11-28 | 2012-11-06 | Shire Llc | Substituted quinazolines for reducing platelet count |
GB0623749D0 (en) * | 2006-11-28 | 2007-01-10 | Shire Llc | Substituted quinazolines |
US7910597B2 (en) * | 2006-11-28 | 2011-03-22 | Shire Llc | Substituted quinazolines |
WO2019080982A1 (en) * | 2017-10-26 | 2019-05-02 | Osaa Innovation Aps | APPARATUS FOR DISPENSING A LIQUID FROM A COMPRESSIBLE BAG |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2862966A (en) | 1958-12-02 | archo | ||
US3932407A (en) | 1973-11-19 | 1976-01-13 | Bristol-Myers Company | Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones |
USRE31617E (en) | 1972-02-04 | 1984-06-26 | Bristol-Myers Company | Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones |
US4146718A (en) | 1978-04-10 | 1979-03-27 | Bristol-Myers Company | Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides |
US4208521A (en) | 1978-07-31 | 1980-06-17 | Bristol-Myers Company | Process for the preparation of imidazo[2,1-b]quinazolinones |
US4357330A (en) | 1981-07-30 | 1982-11-02 | Bristol-Myers Company | Pharmaceutical compositions |
CA2171073A1 (en) * | 1995-12-04 | 1997-06-05 | Philip C. Lang | Process for the preparation of ethyl-n-(2,3 dichloro-6- nitrobenzyl) glycine |
-
1999
- 1999-11-30 US US09/452,008 patent/US6194420B1/en not_active Expired - Lifetime
-
2000
- 2000-11-28 AR ARP000106257A patent/AR026631A1/es unknown
- 2000-11-29 AU AU15381/01A patent/AU1538101A/en not_active Abandoned
- 2000-11-29 WO PCT/GB2000/004561 patent/WO2001040196A1/en active Application Filing
- 2000-11-29 CA CA2392630A patent/CA2392630C/en not_active Expired - Lifetime
- 2000-11-29 UY UY26459A patent/UY26459A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US6194420B1 (en) | 2001-02-27 |
WO2001040196A1 (en) | 2001-06-07 |
UY26459A1 (es) | 2001-06-29 |
CA2392630C (en) | 2010-01-26 |
AU1538101A (en) | 2001-06-12 |
CA2392630A1 (en) | 2001-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0211228A (pt) | Composto, composição farmacêutica e seus usos | |
GEP20053673B (en) | Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents | |
AR054064A1 (es) | Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas | |
WO2005011653A3 (en) | Pyridazine derivatives and their use as therapeutic agents | |
TNSN06034A1 (en) | Pyridazine derivatives and their use as therapeutic agents | |
GEP20074208B (en) | Substituted amides active at the cannabinoid-1 receptor | |
SE9901573D0 (sv) | New compounds | |
SE9900961D0 (sv) | Novel compounds | |
AR006598A1 (es) | "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación" | |
GEP20033079B (en) | Pharmaceutical Compositions for Treatment of Diseases Caused by Estrogens Deficiency | |
SE0302573D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
SE0300908D0 (sv) | Azaindole derivatives, preparations thereof, uses thereof and compositions containing them | |
AR019053A1 (es) | Uso de 2'2'-difluoronucleosidos para la preparacion de un medicamento y composicion farmaceutica y producto farmaceutico que los contienen | |
AR026631A1 (es) | ''3-4-dihidroquinazolinas 5,6-disustituidas'' | |
SE0002476D0 (sv) | New compounds | |
SE0102440D0 (sv) | New compound | |
SE0302570D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
UA83832C2 (ru) | Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и их применение | |
NO912414L (no) | Forbindelse med mavesyreinhiberende effekt og fremgangsmaate for dens fremstilling. | |
SE0302572D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
SE9901572D0 (sv) | New compounds | |
DE69401502T2 (de) | Arzneizubereitung zum Herstellen eines stabilisierten Pulvers das eine Kombination aus Acetylsalicylsäure und Metoclopramid als Wirkstoff enthält | |
MX9304197A (es) | Nuevo uso de dimero de lisozina y composiciones que lo contienen. | |
CA2450915A1 (en) | Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure | |
HUP0000108A2 (hu) | Angiotenzin II antagonisták alkalmazása szimptómás szívelégtelenség kezelésére alkalmas gyógyászati készítmény előállítására |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |